Successful Management of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy (PML) and Immune Reconstitution Syndrome (IRIS) in a Patient With Multiple Sclerosis
Alexandra Schröder, MD; De-Hyung Lee, MD; Kerstin Hellwig, MD;
Carsten Lukas, MD; Ralf A. Linker, MD; Ralf Gold, MD
Arch Neurol. Published online July 12, 2010. doi:10.1001/archneurol.2010.157
Objective To describe a case of successful clinical management of natalizumab-associated progressive multifocal leukoencephalopathy(PML) and immune reconstitution syndrome (IRIS) in a patient with multiple sclerosis.
Design Case report.
Setting University hospital.
Patient A 41-year-old woman with relapsing-remitting multiple sclerosis developed PML after 29 natalizumab infusions.
Interventions Immediate plasma exchange was combined for removal of natalizumab with application of mefloquine and mirtazapine to limit viral replication and oligodendrocyte infection. A subsequent IRIS was treated with glucocorticosteroids.
Results After 3 months of treatment, cerebrospinal fluid tested negative for JC virus. There was a favorable outcome, and the Expanded Disability Status Scale score remained stable at 3.5 compared with before PML.
Conclusions In the setting of early diagnosis and consequent treatment, natalizumab-associated PML can be well managed in some cases. This situation differs from the course of PML in other conditions, eg, after the application of depleting monoclonal antibodies, in which irreversible cellular effects are associated with very high mortality.
Author Affiliations: Departments of Neurology (Drs Schröder, Lee, Hellwig, Linker, and Gold); and Radiology (Dr Lukas), St Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
SOURCE: Archives of Neurology – July 12, 2010 –
Read more of this, from Lori Friend, a writer for the examiner.com by clicking here
*
*